Renaissance Technologies’s Quince Therapeutics QNCX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-2,691
Closed -$1.8M 3601
2025
Q4
$1.8M Buy
2,691
+348
+15% +$175K ﹤0.01% 1927
2025
Q3
$764K Buy
2,343
+444
+23% +$148K ﹤0.01% 2618
2025
Q2
$627K Sell
1,899
-601
-24% -$137K ﹤0.01% 2721
2025
Q1
$665K Sell
2,500
-115
-4% -$35.1K ﹤0.01% 2621
2024
Q4
$978K Buy
2,615
+2
+0.1% +$601 ﹤0.01% 2512
2024
Q3
$406K Buy
2,613
+193
+8% +$27.7K ﹤0.01% 2875
2024
Q2
$363K Sell
2,420
-181
-7% -$32.7K ﹤0.01% 2837
2024
Q1
$551K Buy
2,601
+308
+13% +$76.5K ﹤0.01% 2819
2023
Q4
$482K Buy
2,293
+668
+41% +$134K ﹤0.01% 2798
2023
Q3
$364K Buy
1,625
+181
+13% +$47.3K ﹤0.01% 2851
2023
Q2
$434K Buy
1,444
+295
+26% +$91.8K ﹤0.01% 2949
2023
Q1
$358K Buy
1,149
+378
+49% +$74K ﹤0.01% 3044
2022
Q4
$98K Sell
771
-900
-54% -$151K ﹤0.01% 3624
2022
Q3
$445K Buy
1,671
+274
+20% +$104K ﹤0.01% 2996
2022
Q2
$620K Buy
+1,397
New +$987K ﹤0.01% 3024
2020
Q4
Sell
-22
Closed -$220K 3653
2020
Q3
$220K Sell
22
-113
-84% -$1.03M ﹤0.01% 3076
2020
Q2
$1.25M Buy
135
+110
+440% +$1.01M ﹤0.01% 2437
2020
Q1
$226K Buy
+25
New +$247K ﹤0.01% 3071

Other funds holding QNCX

Renaissance Technologies's QNCX Position: Q1 2026 in Review

Renaissance Technologies sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 2,691 shares — an estimated $1.8M sold.

Renaissance Technologies first reported a position in QNCX in Q1 2020 and held it in 18 quarters. The position peaked at $1.8M in Q4 2025. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Renaissance Technologies reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Renaissance Technologies sold 2,691 Quince Therapeutics shares in Q1 2026, an estimated $1.8M.
  • Renaissance Technologies first reported a position in Quince Therapeutics in Q1 2020 and held it in 18 quarters.
  • Renaissance Technologies's Quince Therapeutics position peaked at $1.8M in Q4 2025.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.